Clinical practice guideline on liver transplantation for hepatocellular carcinoma in China (2021 edition)

作者：Jun Chen, Tian Shen, Jianhui Li, Sunbin Ling, Zhe Yang, Guoying Wang, Liying Sun, Zhao-Xu Yang, Li Zhuang, Jie Gao, Wenyuan Guo, Jie Li, Shengjun Xu, Qiang Wei, Shusen Zheng, Xiao Xu · 发表于：Chinese Medical Journal · 年份：2022 · DOI：10.1097/cm9.0000000000002515 · 被引用次数：30 · 研究领域：Hepatocellular Carcinoma Treatment and Prognosis、Hepatitis B Virus Studies、Organ Transplantation Techniques and Outcomes

Hepatocellular carcinoma (HCC) is the main cause of cancer-related deaths in adult men under the age of 60 years in China.[1] Liver transplantation (LT) is generally recognized as one of the most effective therapeutic approaches for end-stage liver diseases. LT guidelines for HCC were firstly launched in 2014 and were updated in 2018. Recently, further updates are required to adapt to the new situation of LT in China and to continue advancing the recommendations. (Full version in Supplementary file, https://links.lww.com/CM9/B362). The classification of evidence adopted in the guideline mainly refers to the 2001 Oxford evidence classification (Supplementary Table 1, https://links.lww.com/CM9/B362). Criteria of LT for HCC Establishing appropriate LT criteria for HCC patients is key to improving the prognosis and making rational use of the scarce donor-liver resources. The restrictions on tumor size and number render the Milan criteria too restrictive. Hangzhou criteria expand the recipient population safely and combine both tumor biological and pathological characteristics. Salvage LT was feasible for recipients with HCC recurrence after initial partial hepatic resection who met the criteria. The selection criteria for living-related donor LT in HCC candidates can be extended appropriately (Table 1). Table 1 - Clinical practice guidelines on liver transplantation for hepatocellular carcinoma. Item Recommendations Evidence grade Recommendation strength Criteria of liver transpl...